Kornimate/medical-research-clean huggingface dataset:
an efficacy study of chlorhexidine mouthwashes

Conditions: Gingivitis

Summary: the aim of this study is to compare subject gingival health after 6 weeks of twice daily use of a non-alcohol or alcohol containing mouthrinse and brushing compared to brushing only.


Eligibility criteria:
inclusion criteria: * good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/ dental examination. 5. a) good oral health in the opinion of the investigator (allowing mild to moderate gingivitis to meet entry criteria). b) a minimum of 20 permanent gradable teeth at screening. (gradable teeth are those where restorative materials cover less than 25% of the tooth surface graded). c) mild to moderate gingivitis present at the screening visit in the opinion of the investigator. d) positive response to bleeding on brushing exercise at screening visit. e) a total of 20 bleeding sites or greater at baseline visit. exclusion criteria: * known or suspected intolerance or hypersensitivity to chlorhexidine or other study materials (or closely related compounds) or any of their stated ingredients. * 5. a) current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. diabetes mellitus) that would make the subject unlikely to fully complete the study or any that increases the risk to the subject or undermines the data validity. b) subjects requiring prophylactic antibiotic treatment prior to dental therapy. c) use of concomitant medication that, in the opinion of the investigator, might interfere with the outcome of the study or increases the risk to the subject (eg: phenytoin, calcium antagonists, cyclosporine, warfarin, antibiotics, immuno-suppressants). d) use of antibiotics within two weeks prior to the screening visit or throughout the study. e) use of any systemic medication which would have an effect on gingival conditions within 14 days of gingival examinations (eg: ibuprofen or aspirin therapy) 6. a) have current active caries b) more than 3 pockets with 5mm or over. c) excessive calculus present that interferes with the probing examination for gingival index. d) other severe oral/ gingival conditions (e.g. acute necrotizing ulcerative gingivitis) that may compromise the study or the subjects in the opinion of the investigator or gingivitis examiner. e) medical conditions which may directly influence gingival bleeding. f) restorations in a poor state of repair. g) orthodontic appliances anterior cosmetic restorations and veneers. h) enamel pitting/irregularities. 7. subjects using chewing tobacco, pan, pan-masala, gutkha or other chewing tobacco products or subjects who have quit using any of those within the past six months prior to screening. 8. b) an employee of any toothpaste manufacturer or their immediate family.
fixation of thoracic epidurals influencing catheter-related infections and dislocation

Conditions: Dislocation; Infection; Line Colonisation; Line Insertion Site

Summary: major interest in our investigation is to find out whether distinct fixation techniques influence catheter dislocation and/ or incidence of local inflammation. a systematic comparison of two different fixation techniques with regard to catheter location, analgetic potential and signs of local inflammation will be conducted. to ensure identical patients groups allocation will be strictly randomized. furthermore, both patient groups will receive identical pain medication via the peridural catheter in situ. all catheter tips will be screened microbiologically after removal.


Eligibility criteria:
inclusion criteria: patients aged \> 18 years and operation with thoracic epidural exclusion criteria: refusal of informed consent
ozone therapy in the treatment of digital ulcers in patients with systemic sclerosis

Conditions: Ulcer; Scleroderma

Summary: digital ulcers (dus) in scleroderma result from recurrent raynaud's phenomenon (rp) and microtrauma with high impact on quality of life, management of dus is a great challenge for clinicians. medical use of ozone (triatomic oxygen) was initiated in the 19th century. ozone has multiple therapeutic effects in wound healing due to the property of releasing nascent oxygen, which has been shown to stimulate antioxidant enzymes.

digital ulcers (dus) in scleroderma result from recurrent raynaud's phenomenon (rp) and microtrauma with high impact on quality of life, management of dus is a great challenge for clinicians. medical use of ozone (triatomic oxygen) was initiated in the 19th century. ozone has multiple therapeutic effects in wound healing due to the property of releasing nascent oxygen, which has been shown to stimulate antioxidant enzymes, we aim to assess the effects of ozone therapy on the healing in scleroderma dus and the expressions of vascular endothelial growth factor (vegf), and endothelin-1 type a receptor (etar) and angiotensin ii type 1 receptor (at1r) autoantibodies level in the wounds after treatment.

Eligibility criteria:
inclusion criteria: * systemic sclerosis patients with dus fulfilling acr/eular criteria for diagnosis 2013 exclusion criteria: * calcinosis ulcer traumatic ulcer vasculitis

Keywords: ozone oxygen ulcer healing
chronic non-malignant pain in cancer patients at a supportive care clinic

Conditions: Malignant Neoplasms of Independent (Primary) Multiple Sites

Summary: the goal of this research study is to learn how frequently cancer patients in the supportive care center have chronic, non-malignant pain. chronic, non-malignant pain is pain that is neither related to cancer nor its treatment and lasts beyond the normal tissue healing time of 3 months.

if participant is found to be eligible and agrees to take part in this study, participant will be asked to complete 3 questionnaires about participant's pain, pain level, and what drugs participant takes to treat participant's pain. participant will also be asked a few questions about tobacco use. these questionnaires should take about 20 minutes to complete. researchers will also collect information from participant's medical record such as participant's date of birth, sex, race, marital status, economic background, and medical history. length of study: participation on this study will be over after participant has completed the last questionnaire. this is an investigational study. up to 200 participants will be enrolled in this study. all will take part at md anderson.

Eligibility criteria:
inclusion criteria: 1. diagnosis of cancer with or without active disease 2. consultation visit at an outpatient supportive care clinic 3. age 18 or greater 4. report of having pain within the last 3 months exclusion criteria: 1) memorial delirium assessment scale \>13

Keywords: malignant neoplasms of independent (primary) multiple sites non-malignant pain supportive care questionnaires surveys chronic non-malignant pain
a database survey to evaluate the safety of immune globulin subcutaneous (human), 20% solution in participants with primary immunodeficiency

Conditions: Primary Immunodeficiency Diseases (PID)

Summary: this study is a retrospective database study in japan to evaluate the safety of immune globulin subcutaneous (human), 20% solution in participants with primary immunodeficiency disease (pid). this survey will conduct in use of medical database called pidj2.


Eligibility criteria:
inclusion criteria: 1. patients with primary immunodeficiency (pid) enrolled in the pid patient registry. 2. participant for whom study drug is entered in the therapeutic drug field on the data set. 3. participant who is entered the intractable disease diagnosis corresponding to pid in the intractable disease information field. 4. participant for whom the presence or absence of adverse events has been entered in the column of adverse events. exclusion criteria: 1. participant for whom study drug has not been entered in the drug name in the medical history field during the period from january 24, 2024 to january 23, 2029. 2. participant who is not entered the intractable disease diagnosis corresponding to pid in the intractable disease information field. 3. participant for whom the presence or absence of adverse events has not been entered in the column of adverse events.

Keywords: primary immunodeficiency disease
a study comparing the efficacy and safety of pola-rchp-x versus rchop-x and pola-rchp in previously untreated patients with dlbcl

Conditions: Diffuse Large B Cell Lymphoma

Summary: this study aims to compare the efficacy and safety of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone combined with orelabrutinib/chidamide/venetoclax/lenalidomide/pd1 (pola-rchp-x) versus rchop-x and pola-rchp in previously untreated patients with dlbcl.


Eligibility criteria:
inclusion criteria: * sign the informed consent form * previously untreated participants with cd20-positive dlbcl * life expectancy ≥ 6 months * ipi score 2-5 * ecog performance status of 0, 1, or 2 * left ventricular ejection fraction (lvef) ≥ 50% on cardiac multiple-gated acquisition (muga) scan or cardiac echocardiogram (echo) * adequate hematologic function (unless due to underlying disease, as established for example, by extensive bone marrow involvement or due to hypersplenism secondary to involvement of the spleen by dlbcl per the investigator for which blood product transfusions are permitted) defined as follows: hemoglobin ≥ 9.0 g/dl without packed rbc transfusion during 7 days before first treatment anc ≥ 1.0 x 10\^9/l plt ≥ 75 x 10\^9/l exclusion criteria: * contraindication to any of the individual components of pola-rchp or orelabrutinib/chidamide/venetoclax/lenalidomide/pd1 * history of other malignancy that could affect compliance with the protocol or interpretation of results * significant or extensive history of cardiovascular disease such as new york heart association class iii or iv cardiac disease or objective assessment class c or d, myocardial infarction within the last 6 months prior to the start of cycle 1, unstable arrhythmias, or unstable angina * history or presence of an abnormal ecg that is clinically significant in the investigator's opinion * any active infection within 7 days prior to cycle 1 day 1 that would impact participant safety * any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma): serum ast and alt ≥ 2.5 x uln total bilirubin ≥ 1.5 x uln serum creatinine clearance \< 40 ml/min (using cockcroft-gault formula) * suspected active or latent tuberculosis (as confirmed by a positive interferon-gamma release assay) * participants with a history of progressive multifocal leukoencephalopathy
the effects of healthy diets with plant oils on heart and metabolic health

Conditions: Cardiovascular Diseases

Summary: this study will examine the effect of a healthy diet containing cottonseed oil compared to healthy diets containing other commonly consumed plant oils on biomarkers of heart and metabolic health after 4 weeks.

this is a 3-period randomized crossover complete feeding study examining if a dietary pattern containing cottonseed oil improves lipids/lipoproteins and other cardiometabolic disease risk factors to a greater extent than a fatty acid matched diet devoid of cottonseed oil and a diet lower in polyunsaturated fatty acids (pufa) and saturated fatty acids (sfa), but with a matched pufa:sfa ratio

Eligibility criteria:
inclusion criteria: * ldl-c ≥100 mg/dl and ≤190 mg/dl * bmi of 25-40 kg/m2 * blood pressure \<140/90 mmhg * fasting blood glucose \<126 mg/dl * fasting triglycerides \<350 mg/dl * ≤10% change in body weight for 6 months prior to enrollment exclusion criteria: * type 1 or type 2 diabetes or fasting blood glucose ≥126 mg/dl * prescription of anti-hypertensive, lipid lowering or glucose lowering drugs * intake of supplements that affect the outcomes of interest and unwilling to cease during the study period * diagnosed liver, kidney, or autoimmune disease * prior cardiovascular event (e.g., stroke, heart attack) * current pregnancy or intention of pregnancy within the next 6 months * lactation within prior 6 months * follows a vegetarian or vegan diet * food allergies/intolerance/sensitives/dislikes of foods included in the study menu * antibiotic use within the prior 1 month * oral steroid use within the prior 1 month * use of tobacco or nicotine containing products with in the past 6 months * cancer any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer with in the past 5 years (eligible if ≥5 years without recurrence) * participation in another clinical trial within 30 days of baseline * currently following a restricted or weight loss diet * prior bariatric surgery * intake of \>14 alcoholic drinks/week and/or lack of willingness to consume a maximum of two standard drinks per week while enrolled in the study and/or not willing to avoid alcohol consumption for 48 hour prior to test visits
a study of the safety and efficacy of the vytronus low-intensity collimated ultrasound ablation system

Conditions: Paroxysmal Atrial Fibrillation

Summary: the objective of this investigation is to evaluate whether pulmonary vein isolation using the vytronus ablation system is safe and effective acutely and at 3 months.


Eligibility criteria:
inclusion criteria: * age 18 to 70 years old. * recurrent symptomatic paroxysmal atrial fibrillation refractory to at least one antiarrhythmic drug. exclusion criteria: * prior pulmonary vein isolation * presence of intracardiac thrombus * indication of inaccessible pulmonary or cardiac anatomy * myocardial infarction, pci, or cardiac surgery in prior three months * moderate to severe valvular disease or prior valve replacement * nyha class iv * lvef \< 40% * previous stroke or tia * serum creatinine \> 2.5mg/dl or allergy to intravenous contrast agents * existing bleeding diathesis or history of complications with anticoagulation therapy * women who are nursing, pregnant, or trying to become pregnant * subjects unwilling or unable to provide consent * participation in a drug or device trial that would prevent completion of required study procedures * active implantable devices * major organ system disease
clinical results and rsa migration analysis of the global icon - stemless anatomic shoulder

Conditions: Osteoarthritis of the Shoulder

Summary: the primary goal of the clinical trial is to determine that the global icon implant system from depuy does not exhibit worse shoulder function after 2 years than the simplicity from wright medical. the primary endpoint is the constant-murley shoulder score (cmss) of the implant after 2 years, the non-inferiority of which is to be demonstrated in comparison with an already established prosthetic system (simplicity, wright medical).

the primary goal of the clinical trial is to determine that the global icon implant system from depuy does not exhibit worse shoulder function after 2 years than the simplicity from wright medical. the primary endpoint is the constant-murley shoulder score (cmss) of the implant after 2 years, the non-inferiority of which is to be demonstrated in comparison with an already established prosthetic system (simplicity, wright medical). as secondary endpoints, the migration behavior of the humeral components over time will be determined by radiostereometric analysis (rsa), the further clinical-functional results and the satisfaction of the patients treated will be investigated. clinical outcomes are measured using standardized and reproducible clinical scores (oxford shoulder score -oss and short form health 36-sf-36 v1.0 ) at each time of examination. other endpoints include revision rate within the follow-up period, surgical time (incision to suture), and delays in surgical procedures due to instrumentation. the times of data acquisition are the admission day before the operation to determine the preoperative status, the discharge day and the follow-up appointments after 3 months, 6 months, 12 months and 24 months to determine the postoperative status and course.

Eligibility criteria:
inclusion criteria: 1. trial participants need primary total shoulder replacement due to primary osteoarthritis or post-traumatic osteoarthritis 2. trial participants are willing to take part in the clinical trial and intend to be available for the planned follow-up examinations. 3. male, female and various subjects with age on the day of surgery from 18 to 80 years inclusive. 4. subjects agree not to participate in any other clinical trial for at least 2 years (+ 3 weeks) using the index procedure. this includes clinical trials of medication, invasive procedures and medical devices. questionnaire-based studies or other studies that are non-invasive and do not involve drug use are allowed. 5. exclusion of intraoperative circumstances that require the implantation of a prosthesis type other than that provided for in the clinical trial (depending on the surgeon). exclusion criteria: 1. previous operation on the rotator cuff of the affected shoulder 2. dysfunctional rotator cuff 3. infection of the affected shoulder joint or systemic infection 4. pregnant or breastfeeding women and those who are planning to become pregnant for up to 2 years (+3 weeks) using the index procedure

Keywords: osteoarthritis shoulder joint replacement
carmustine and o(6)-benzylguanine in treating patients with newly diagnosed supratentorial glioblastoma multiforme

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. o(6)-benzylguanine may increase the effectiveness of carmustine by making tumor cells more sensitive to the drug. purpose: phase ii trial to study the effectiveness of combining carmustine with o(6)-benzylguanine in treating patients who have newly diagnosed supratentorial glioblastoma multiforme.

objectives: * determine the activity of carmustine and o6-benzylguanine in patients with newly diagnosed supratentorial glioblastoma multiforme not requiring immediate radiotherapy. * determine the toxicity of this regimen in these patients. outline: patients receive o6-benzylguanine iv over 1 hour followed approximately 1 hour later by carmustine iv over 1 hour on day 1. treatment repeats every 6 weeks for a maximum of 3 courses in the absence of disease progression or unacceptable toxicity. patients are then referred for radiotherapy. patients who demonstrate tumor response after completion of the third course of chemotherapy receive 6 additional courses after completion of radiotherapy. projected accrual: a total of 19-36 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed newly diagnosed supratentorial glioblastoma multiforme not requiring immediate radiotherapy * measurable residual disease on a contrast-enhanced mri or ct scan (for patients with a medical contraindication for mri) with a baseline scan obtained at the corticosteroid dose the patient is receiving on the day of treatment patient characteristics: age * 18 and over performance status * karnofsky 60-100% life expectancy * not specified hematopoietic * absolute granulocyte count at least 1,500/mm3 * platelet count at least 100,000/mm3 * hemoglobin greater than 10 g/dl hepatic * bilirubin normal * sgot no greater than 2.5 times upper limit of normal renal * creatinine no greater than 1.5 mg/dl * bun no greater than 25 mg/dl pulmonary * dlco greater than 75% predicted other * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 2 months after study prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * see disease characteristics * concurrent corticosteroids allowed if on stable dose for 3 days before study radiotherapy * see disease characteristics surgery * no more than 28 days since prior surgical resection or biopsy

Keywords: adult glioblastoma adult giant cell glioblastoma adult gliosarcoma
covid-19 burnout study

Conditions: Stress

Summary: the aims of this study are to assess whether the use of a mbi therapy delivered remotely is associated with a reduction of perceived stress among hcps in the radiation medicine program (rmp) and with a decrease risk of burnout during and post covid-19.


Eligibility criteria:
inclusion criteria: * -employee in the radiation medicine program in uhn * health care professional (therapist, nurse, physician, resident, physician assistant, physician admin assistant) * over 18 exclusion criteria: * not working at the radiation medicine program at uhn
interventions for sanctioned ohio university students

Conditions: Alcohol Drinking

Summary: the purpose of this study is to determine whether (a) a brief alcohol intervention, (b) a brief bystander and social norms intervention, or (c) a brief alcohol and a brief bystander and social norms intervention are effective at reducing alcohol use and sexual-related behaviors among college men mandated to receive an alcohol intervention by their university.


Eligibility criteria:
inclusion criteria: * must be 18 or older; must be an ohio university student; must be male; must be sanctioned to receive an alcohol intervention by ohio university exclusion criteria: * under the age of 18; not attending the main ohio university campus (athens)
pilot study of the tearcare system

Conditions: Dry Eye

Summary: the purpose of this study is to evaluate the clinical utility, safety, and effectiveness of the tearcare™ system compared to standardized warm compress therapy for the application of controlled, localized heat therapy in adult patients with dry eye syndrome.


Eligibility criteria:
inclusion criteria: * dry eye symptoms within 30 months of the screening exam with a speed score \>=6 * schirmer 1 value of \<010 mm in at least one eye or a tear breakup time \<10 seconds in at least one eye exclusion criteria: * any active ocular or peri-ocular infection or inflammation * recurrent eye inflammation within the past 3 months * ocular surgery, oculoplastic surgery, ocular injury, ocular herpes simplex, or herpes zoster * ocular surface abnormalities that may affect tear film distribution or treatment * abnormal eyelid function in either eye * diminished or abnormal facial, periocular, ocular or corneal sensation * ocular surface abnormalities such as corneal epithelial defects, ulcers, corneal dystrophies * systemic diseases resulting in dry eye (e.g. sjogren's syndrome) * allergies to silicone tissue adhesives * an absence or fibrosis of the meibomian glands (e.g. ectodermal dysplasia). * unwillingness to abstain for the duration of the study from systemic medication known to cause ocular dryness (e.g. accutane, antihistamines, etc.) * anyone who requires chronic use (i.e. for any portion of the study) of topical ophthalmic antibiotics, steroids, non-steroidal anti-inflammatory medications or who has been on any of these medications within the past 30 days. * unwillingness to washout and remain off certain dry eye medications for the duration of the study. * participation in another ophthalmic clinical trial within the past 30 days * co-existing conditions that could interfere with the assessment of safety or efficacy of treatment (e.g. macular disease, pregnancy, nursing, etc.)
comparing an automated to a conventional sepsis clinical prediction rule

Conditions: Sepsis

Summary: the investigators will conduct a prospective cohort study to compare an automated sepsis severity score to a conventional clinical prediction rule to risk stratify patients admitted from the emergency department (ed) with suspected infection for 28 day in-hospital mortality.


Eligibility criteria:
inclusion criteria: * all consecutive adult (age 18 or older) emergency department (ed) patients during the study period that have been admitted from the ed and identified by the treating clinician to have a suspected infection at the time of ed disposition will comprise our study population. exclusion criteria: * no patients will be excluded from the study.

Keywords: sepsis clinical prediction rule clinical informatics machine learning